Netherlands· NL-544362c18cb2
Steglujan 5 mg/50 mg filmomhulde tabletten
A sitagliptin and ertugliflozin product containing ertugliflozine-l-pyroglutaminezuur + sitagliptinefosfaat 1-water, registered in Netherlands by Merck Sharp & Dohme B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Sitagliptin and ertugliflozin is registered in 10 of 19 countries.
Countries holding a registration under ATC A10BD24 (sitagliptin and ertugliflozin), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Sitagliptin and ertugliflozin · ATC A10BD24
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ERTUGLIFLOZINE-L-PYROGLUTAMINEZUUR + SITAGLIPTINEFOSFAAT 1-WATER
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Netherlands (NL)
- ATC code
- A10BD24
- ATC class
- Sitagliptin and ertugliflozin
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/18/1266
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under A10BD24
Sitagliptin and ertugliflozin, as other registers publish it.
- IcelandSteglujanMerck Sharp & Dohme B.V.*
- FinlandSteglujanMerck Sharp & Dohme B.V.
- PolandSteglujanMerck Sharp & Dohme B.V.
- PolandSteglujanMerck Sharp & Dohme B.V.
- FinlandSteglujanMerck Sharp & Dohme B.V.
- DenmarkSteglujanMerck Sharp & Dohme B.V.
- IcelandSteglujanMerck Sharp & Dohme B.V.*
- DenmarkSteglujanMerck Sharp & Dohme B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ba504c66-04b7-4f16-8205-ce63c7f7002f GET /v1/drugs/ba504c66-04b7-4f16-8205-ce63c7f7002f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/steglujan-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Sitagliptin and ertugliflozin",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp120653",
"excipients": [
"CALCIUMWATERSTOFFOSFAAT 0-WATER (E 341)",
"CARNAUBAWAS (E 903)",
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"HYPROLOSE (E 463)",
"HYPROMELLOSE (E 464)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ROOD (E 172)",
"IJZEROXIDE ZWART (E 172)",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMSTEARYLFUMARAAT",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"ERTUGLIFLOZINE-L-PYROGLUTAMINEZUUR",
"SITAGLIPTINEFOSFAAT 1-WATER"
],
"leaflet_url": null,
"authorised_at": "2018/03/23",
"procedure_number": "EMEA/H/C/004313",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/18/1266",
"additional_monitoring": "N"
}See everything about sitagliptin and ertugliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.